| Trial ID: | L4793 |
| Source ID: | NCT04970108
|
| Associated Drug: |
Egito
|
| Title: |
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
|
| Acronym: |
EGITO
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension Associated|Type II Diabetes Mellitus
|
| Interventions: |
DRUG: Egito|DRUG: Empagliflozin + telmisartan
|
| Outcome Measures: |
Primary: Glycated hemoglobin, Changes from baseline in glycated hemoglobin, 120 days|Systolic blood pressure (SBP), Changes from baseline in SBP in ambulatory blood pressure monitoring, 120 days | Secondary: Adverse events, Incidence and severity of adverse events recorded during the study, 150 days
|
| Sponsor/Collaborators: |
Sponsor: EMS
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2023-08
|
| Completion Date: |
2025-05
|
| Results First Posted: |
|
| Last Update Posted: |
2023-09-08
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT04970108
|
